Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Terns Pharmaceuticals
Biotech
As Madrigal lands MASH nod, what's next for biotechs in pursuit?
Madrigal’s MASH drug has been approved. For the other companies with up-and-coming treatments trailing in the clinic, the question is: What now?
Annalee Armstrong
Mar 15, 2024 10:55am
Takeda welcomes new oncology chief from CRISPR—Chutes & Ladders
Feb 9, 2024 9:30am
Terns bows out of MASH race, reverts back to phase 1
Jan 5, 2024 9:57am
Akero's NASH miss drags a few peers down, spurring deja vu
Oct 11, 2023 10:50am
Prospective NASH market flips from failure to overcrowded
Aug 10, 2023 6:00am
Terns’ phase 2 NASH trial hits but differentiation doubts go on
Aug 9, 2023 4:43am